{"id":"baraclude-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Lactic acidosis (rare but serious)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Entecavir is a nucleoside analog that selectively inhibits HBV polymerase (reverse transcriptase), preventing the virus from copying its genetic material and reducing viral load. It has high specificity for HBV and minimal activity against other viruses, making it a potent and selective antiviral agent for chronic hepatitis B infection.","oneSentence":"Baraclude (entecavir) inhibits hepatitis B virus reverse transcriptase, blocking viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:20:31.012Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection in adults"},{"name":"Chronic hepatitis B infection in children and adolescents"}]},"trialDetails":[{"nctId":"NCT07493109","phase":"PHASE3","title":"Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-05-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":200},{"nctId":"NCT04536337","phase":"PHASE1","title":"A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects","status":"COMPLETED","sponsor":"Aligos Therapeutics","startDate":"2020-10-22","conditions":"Chronic Hepatitis B","enrollment":165},{"nctId":"NCT06990776","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects","status":"WITHDRAWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-07-09","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT05123599","phase":"PHASE1","title":"A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-12-06","conditions":"Hepatitis B, Chronic","enrollment":24},{"nctId":"NCT04585789","phase":"PHASE2","title":"A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-11","conditions":"Hepatitis B","enrollment":24},{"nctId":"NCT06966232","phase":"PHASE3","title":"Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-15","conditions":"Gastrointestinal Cancers","enrollment":136},{"nctId":"NCT05182463","phase":"PHASE4","title":"Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-01-08","conditions":"Hepatitis B, Chronic","enrollment":5000},{"nctId":"NCT04535544","phase":"PHASE2","title":"A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-17","conditions":"Hepatitis D, Chronic","enrollment":52},{"nctId":"NCT05275023","phase":"PHASE2","title":"An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-06-30","conditions":"Hepatitis B, Chronic","enrollment":37},{"nctId":"NCT06000657","phase":"PHASE4","title":"Efficacy and Safety of Switching to Vemliver From Entecavir in Chronic Hepatitis B Patients Previously Treated With Entecavir","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2023-08-28","conditions":"Hepatitis B, Chronic","enrollment":196},{"nctId":"NCT04129554","phase":"PHASE2","title":"A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2019-11-06","conditions":"Hepatitis B, Chronic","enrollment":130},{"nctId":"NCT03982186","phase":"PHASE2","title":"A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2019-08-01","conditions":"Hepatitis B, Chronic","enrollment":471},{"nctId":"NCT05423106","phase":"PHASE1","title":"A Single and Multiple Ascending Dose Study of JNJ-64457744","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-04","conditions":"Healthy, Hepatitis B, Chronic","enrollment":60},{"nctId":"NCT06150014","phase":"PHASE1, PHASE2","title":"A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-12-07","conditions":"Chronic Hepatitis b","enrollment":88},{"nctId":"NCT06566248","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-03-20","conditions":"Chronic Hepatitis B","enrollment":90},{"nctId":"NCT04667104","phase":"PHASE2","title":"A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-02-01","conditions":"Hepatitis B, Chronic","enrollment":48},{"nctId":"NCT04536532","phase":"PHASE1, PHASE2","title":"Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study","status":"TERMINATED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2020-10-09","conditions":"Hepatitis B, Chronic","enrollment":52},{"nctId":"NCT04147208","phase":"PHASE2","title":"Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2019-02-28","conditions":"Chronic HBV Infection","enrollment":250},{"nctId":"NCT05107778","phase":"PHASE2","title":"Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2022-01-10","conditions":"Hepatitis B, Chronic","enrollment":43},{"nctId":"NCT06323681","phase":"NA","title":"Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study）","status":"RECRUITING","sponsor":"Qing XIe","startDate":"2024-02-04","conditions":"Chronic Hepatitis b","enrollment":2016},{"nctId":"NCT05005507","phase":"PHASE2","title":"A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-11-03","conditions":"Hepatitis B, Chronic","enrollment":1},{"nctId":"NCT04820686","phase":"PHASE2","title":"A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2021-05-07","conditions":"Chronic Hepatitis B","enrollment":65},{"nctId":"NCT03905655","phase":"PHASE2","title":"Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2019-10-22","conditions":"Chronic Hepatitis B","enrollment":51},{"nctId":"NCT04781647","phase":"PHASE2","title":"A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2021-02-18","conditions":"Chronic Hepatitis B","enrollment":54},{"nctId":"NCT03780543","phase":"PHASE2","title":"A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2018-12-20","conditions":"Chronic Hepatitis B","enrollment":92},{"nctId":"NCT05391360","phase":"PHASE1","title":"Evaluation Freethiadine Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-10-11","conditions":"Hepatitis B, Chronic","enrollment":128},{"nctId":"NCT04864366","phase":"","title":"Efficacy and Safety of TAF for 48 Weeks in HBeAg Positive CHB Patients","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2021-04-30","conditions":"Chronic Hepatitis B","enrollment":150},{"nctId":"NCT03361956","phase":"PHASE2","title":"An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2018-02-13","conditions":"Hepatitis B","enrollment":232},{"nctId":"NCT04465916","phase":"PHASE2","title":"Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)","status":"TERMINATED","sponsor":"Enyo Pharma","startDate":"2020-05-12","conditions":"Hepatitis B, Chronic","enrollment":26},{"nctId":"NCT04454567","phase":"PHASE2","title":"A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2020-11-11","conditions":"Chronic Hepatitis B","enrollment":2},{"nctId":"NCT04398134","phase":"PHASE2","title":"A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2020-08-28","conditions":"Chronic Hepatitis B","enrollment":88},{"nctId":"NCT04365933","phase":"PHASE2","title":"A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir","status":"COMPLETED","sponsor":"Enyo Pharma","startDate":"2020-05-25","conditions":"Hepatitis B, Chronic","enrollment":20},{"nctId":"NCT05416008","phase":"","title":"The Relationship Between Long-term Oral Anti Hepatitis B Nucleoside Analogs and Hepatic Steatosis","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2021-07-01","conditions":"Hepatic Steatosis","enrollment":150},{"nctId":"NCT02862548","phase":"PHASE2","title":"Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-09-16","conditions":"Chronic Hepatitis B","enrollment":51},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT03491553","phase":"PHASE2","title":"Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-04-06","conditions":"Chronic Hepatitis B","enrollment":48},{"nctId":"NCT03241641","phase":"PHASE4","title":"Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.","status":"COMPLETED","sponsor":"Young-Suk Lim","startDate":"2017-10-26","conditions":"Chronic Hepatitis b","enrollment":174},{"nctId":"NCT03576066","phase":"PHASE2","title":"A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2018-06-11","conditions":"Chronic Hepatitis B","enrollment":73},{"nctId":"NCT03577171","phase":"PHASE2","title":"A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2018-06-19","conditions":"Chronic Hepatitis B","enrollment":25},{"nctId":"NCT02263079","phase":"PHASE3","title":"A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-06-16","conditions":"Pediatric Immuno-Tolerant Chronic Hepatitis B","enrollment":62},{"nctId":"NCT03258710","phase":"PHASE4","title":"A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-10-02","conditions":"Hepatitis B, Chronic","enrollment":75},{"nctId":"NCT02945956","phase":"PHASE4","title":"Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2018-04-05","conditions":"Portal Hypertension","enrollment":192},{"nctId":"NCT02945982","phase":"PHASE4","title":"Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2018-04-05","conditions":"Portal Hypertension","enrollment":184},{"nctId":"NCT04180150","phase":"PHASE2","title":"A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-11-18","conditions":"Chronic Hepatitis B","enrollment":12},{"nctId":"NCT04157257","phase":"PHASE2","title":"An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2019-07-26","conditions":"Chronic Hepatitis b","enrollment":60},{"nctId":"NCT03662568","phase":"PHASE1","title":"A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2018-06-26","conditions":"Chronic Hepatitis B","enrollment":56},{"nctId":"NCT04051437","phase":"PHASE3","title":"Plasma Exchange in Acute on Chronic Liver Failure","status":"UNKNOWN","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2019-08-15","conditions":"Cirrhosis, Liver, Acute-On-Chronic Liver Failure","enrollment":130},{"nctId":"NCT01079806","phase":"PHASE3","title":"A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-06-30","conditions":"Chronic Hepatitis B Virus, Pediatric","enrollment":180},{"nctId":"NCT02908191","phase":"PHASE1","title":"A Study in Healthy Volunteers and Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2016-11","conditions":"Chronic Hepatitis B","enrollment":86},{"nctId":"NCT03847246","phase":"NA","title":"Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2018-12-04","conditions":"Chronic Hepatitis b","enrollment":26},{"nctId":"NCT02777814","phase":"PHASE2","title":"Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-05-01","conditions":"Colorectal Neoplasms","enrollment":50},{"nctId":"NCT02241590","phase":"PHASE4","title":"Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2014-09","conditions":"Liver Cirrhosis Due to Hepatitis B Virus","enrollment":700},{"nctId":"NCT02241616","phase":"PHASE4","title":"Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2014-09","conditions":"Hepatitis B Virus Related Cirrhosis","enrollment":350},{"nctId":"NCT03680183","phase":"","title":"Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV)","status":"UNKNOWN","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2018-05-22","conditions":"Non Small Cell Lung Cancer, Hepatitis B","enrollment":300},{"nctId":"NCT03272009","phase":"PHASE1","title":"Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects","status":"COMPLETED","sponsor":"Enyo Pharma","startDate":"2017-09-21","conditions":"Hepatitis B, Chronic","enrollment":73},{"nctId":"NCT00388674","phase":"","title":"Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-12-18","conditions":"Chronic Hepatitis B","enrollment":12522},{"nctId":"NCT01943617","phase":"PHASE4","title":"Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2013-06","conditions":"Liver Cirrhosis","enrollment":606},{"nctId":"NCT01938820","phase":"PHASE4","title":"Optimized Treatment and Regression of HBV-induced Early Cirrhosis","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2013-06","conditions":"Liver Cirrhosis","enrollment":82},{"nctId":"NCT01938781","phase":"PHASE4","title":"Optimized Treatment and Regression of HBV-induced Liver Fibrosis","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2013-06","conditions":"Liver Fibrosis","enrollment":400},{"nctId":"NCT03469583","phase":"PHASE1","title":"Drug Drug Interaction Study for EYP001 With Entecavir","status":"COMPLETED","sponsor":"Enyo Pharma","startDate":"2018-02-12","conditions":"Hepatitis B, Chronic","enrollment":16},{"nctId":"NCT03109730","phase":"PHASE1, PHASE2","title":"Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2017-06-15","conditions":"Chronic Hepatitis B","enrollment":38},{"nctId":"NCT03239353","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects","status":"COMPLETED","sponsor":"Aucta Pharmaceuticals, Inc","startDate":"2017-10-20","conditions":"HBV","enrollment":40},{"nctId":"NCT00423891","phase":"PHASE1, PHASE2","title":"A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-06-30","conditions":"Hepatitis B, Chronic","enrollment":64},{"nctId":"NCT01926288","phase":"PHASE4","title":"Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2008-10","conditions":"Chronic Hepatitis B","enrollment":287},{"nctId":"NCT03032536","phase":"PHASE1","title":"Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers","status":"TERMINATED","sponsor":"Alios Biopharma Inc.","startDate":"2017-01-31","conditions":"Hepatitis B, Chronic Hepatitis B, Viral Hepatitis B","enrollment":54},{"nctId":"NCT02777801","phase":"PHASE2","title":"Prophylactic or Preemptive Entecavir in Patients With Gastric Cancer Who Are Inactive Hepatitis B Carriers","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-06","conditions":"Stomach Neoplasms","enrollment":50},{"nctId":"NCT01913431","phase":"PHASE4","title":"Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2013-09-12","conditions":"HBeAg-Positive Chronic Hepatitis B","enrollment":118},{"nctId":"NCT03062813","phase":"PHASE4","title":"Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN)","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2017-02-01","conditions":"Hepatitis B Virus Associated Nephrotic Syndrome","enrollment":112},{"nctId":"NCT02973646","phase":"PHASE4","title":"Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-01","conditions":"Chronic Hepatitis b","enrollment":100},{"nctId":"NCT00096811","phase":"","title":"Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program","status":"NO_LONGER_AVAILABLE","sponsor":"Bristol-Myers Squibb","startDate":"2003-09","conditions":"Hepatitis B, Chronic Disease","enrollment":""},{"nctId":"NCT01480284","phase":"PHASE3","title":"Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11","conditions":"Hepatitis B, Chronic","enrollment":166},{"nctId":"NCT02850848","phase":"PHASE4","title":"Pharmacokinetics of Two Formulations of Entecavir","status":"COMPLETED","sponsor":"Yung Shin Pharm. Ind. Co., Ltd.","startDate":"2015-12","conditions":"Hepatitis B","enrollment":39},{"nctId":"NCT02615639","phase":"PHASE1, PHASE2","title":"A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-11","conditions":"Chronic Hepatitis B","enrollment":450},{"nctId":"NCT01204762","phase":"PHASE2","title":"Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-11","conditions":"Hepatitis B Virus","enrollment":197},{"nctId":"NCT01341106","phase":"PHASE4","title":"Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2011-04","conditions":"Hepatitis B, Chronic, Liver Fibrosis","enrollment":7},{"nctId":"NCT00986778","phase":"PHASE4","title":"Entecavir Plus Adefovir in Lamivudine-Resistant Patients","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Hepatitis B, Chronic","enrollment":""},{"nctId":"NCT02412319","phase":"PHASE4","title":"The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection","status":"UNKNOWN","sponsor":"Shineway Pharmaceutical Co.,Ltd","startDate":"2014-10","conditions":"HBeAg Positive Chronic Hepatitis B","enrollment":288},{"nctId":"NCT01063036","phase":"PHASE3","title":"Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-05","conditions":"Chronic Hepatitis B","enrollment":144},{"nctId":"NCT00393484","phase":"PHASE4","title":"A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-02","conditions":"Chronic Hepatitis B","enrollment":122},{"nctId":"NCT02075294","phase":"","title":"Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Ying-Jie Ji","startDate":"2010-01","conditions":"Hepatitis B, Chronic","enrollment":242},{"nctId":"NCT01546116","phase":"PHASE4","title":"Adefovir and Lamivudine for Entecavir Resistance (ALTER Study)","status":"COMPLETED","sponsor":"Korea University","startDate":"2010-02","conditions":"Chronic Hepatitis B","enrollment":20},{"nctId":"NCT00410202","phase":"PHASE3","title":"Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-03","conditions":"Hepatitis B, Chronic","enrollment":629},{"nctId":"NCT01894269","phase":"PHASE4","title":"Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-07","conditions":"Hepatocellular Carcinoma","enrollment":200},{"nctId":"NCT00065507","phase":"PHASE3","title":"Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2003-08","conditions":"Hepatitis B","enrollment":195},{"nctId":"NCT00298363","phase":"PHASE2","title":"Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2006-04","conditions":"Chronic Hepatitis B","enrollment":112},{"nctId":"NCT00410072","phase":"PHASE3","title":"Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-04","conditions":"Hepatitis B, Chronic","enrollment":669},{"nctId":"NCT00718887","phase":"PHASE4","title":"Suboptimal Responders to Adefovir Switching to Entecavir","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-07","conditions":"Hepatitis B, Chronic","enrollment":228},{"nctId":"NCT01026610","phase":"PHASE2","title":"Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2009-08","conditions":"Chronic Hepatitis B","enrollment":115},{"nctId":"NCT01438424","phase":"PHASE2","title":"Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-01","conditions":"Hepatitis B Virus, HBV","enrollment":1053},{"nctId":"NCT00395018","phase":"PHASE3","title":"Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-04","conditions":"Hepatitis B, Chronic","enrollment":109},{"nctId":"NCT00371150","phase":"PHASE4","title":"Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-11","conditions":"Hepatitis B Infection","enrollment":131},{"nctId":"NCT01242787","phase":"PHASE2","title":"Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B","status":"UNKNOWN","sponsor":"LG Life Sciences","startDate":"2010-08","conditions":"Chronic Hepatitis B","enrollment":115},{"nctId":"NCT01037166","phase":"PHASE2","title":"Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-12","conditions":"Chronic Hepatitis B","enrollment":84},{"nctId":"NCT01037062","phase":"PHASE2","title":"An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2003-12","conditions":"Chronic Hepatitis B","enrollment":282},{"nctId":"NCT01270178","phase":"","title":"Entecavir for Chronic Hepatitis B in Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation Therapy","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2011-01","conditions":"Chronic Hepatitis B, Hepatocellular Carcinoma","enrollment":420},{"nctId":"NCT00605384","phase":"PHASE3","title":"A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2008-08","conditions":"Chronic Hepatitis B","enrollment":4},{"nctId":"NCT00096785","phase":"PHASE3","title":"Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-12","conditions":"Hepatitis B, Chronic Disease","enrollment":69},{"nctId":"NCT01020565","phase":"PHASE2","title":"A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2003-02","conditions":"Chronic Hepatitis B","enrollment":60},{"nctId":"NCT01148576","phase":"PHASE4","title":"Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2010-06","conditions":"Chronic Hepatitis B, Hepatic Steatosis","enrollment":1200},{"nctId":"NCT00975091","phase":"PHASE3","title":"Continue Entecavir Rollover From China","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-05","conditions":"Chronic Hepatitis B Virus","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Baraclude tablets","genericName":"Baraclude tablets","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Baraclude (entecavir) inhibits hepatitis B virus reverse transcriptase, blocking viral replication. Used for Chronic hepatitis B infection in adults, Chronic hepatitis B infection in children and adolescents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}